{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:54:14Z","timestamp":1771606454606,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010124","name":"Erich und Gertrud Roggenbuck-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.cellsig.2024.111270","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T12:37:42Z","timestamp":1718973462000},"page":"111270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells"],"prefix":"10.1016","volume":"121","author":[{"given":"Daniel J.","family":"Smit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Brauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6khan","family":"Yigit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Therese","family":"Haider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Pogenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"J\u00fccker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cellsig.2024.111270_bb0005","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111270_bb0010","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.cellsig.2024.111270_bb0015","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrc1370","article-title":"Dissecting the metastatic cascade","volume":"4","author":"Pantel","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.cellsig.2024.111270_bb0020","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","article-title":"Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis","volume":"158","author":"Aceto","year":"2014","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111270_bb0025","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1373\/clinchem.2012.194258","article-title":"Circulating tumor cells: liquid biopsy of cancer","volume":"59","author":"Alix-Panabieres","year":"2013","journal-title":"Clin. Chem."},{"issue":"5","key":"10.1016\/j.cellsig.2024.111270_bb0030","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","article-title":"Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy","volume":"6","author":"Alix-Panabieres","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cellsig.2024.111270_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114589","article-title":"Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy","volume":"188","author":"Smit","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cellsig.2024.111270_bb0040","doi-asserted-by":"crossref","DOI":"10.1007\/s10585-024-10267-5","article-title":"Clinical applications of circulating tumor cells in patients with solid tumors","author":"Smit","year":"2024","journal-title":"Clin. Exp. Metastasis"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111270_bb0045","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1186\/1471-2407-14-512","article-title":"Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients","volume":"14","author":"Wallwiener","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cellsig.2024.111270_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2024.101258","article-title":"Circulating tumor cells as liquid biopsy markers in cancer patients","volume":"96","author":"Smit","year":"2024","journal-title":"Mol. Asp. Med."},{"issue":"8","key":"10.1016\/j.cellsig.2024.111270_bb0055","doi-asserted-by":"crossref","first-page":"977","DOI":"10.6004\/jnccn.2013.0118","article-title":"Analysis of circulating tumor cells in breast cancer","volume":"11","author":"Eroglu","year":"2013","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"4","key":"10.1016\/j.cellsig.2024.111270_bb0060","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(14)70069-5","article-title":"Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data","volume":"15","author":"Bidard","year":"2014","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.cellsig.2024.111270_bb0065","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1158\/1078-0432.CCR-15-1603","article-title":"Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast Cancer","volume":"22","author":"Janni","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.cellsig.2024.111270_bb0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease - latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.cellsig.2024.111270_bb0075","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","article-title":"Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells","volume":"19","author":"Keller","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.cellsig.2024.111270_bb0080","doi-asserted-by":"crossref","first-page":"815","DOI":"10.18632\/oncoscience.195","article-title":"Cell lines from circulating tumor cells","volume":"2","author":"Pantel","year":"2015","journal-title":"Oncoscience"},{"issue":"12","key":"10.1016\/j.cellsig.2024.111270_bb0085","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1158\/0008-5472.CAN-15-0145","article-title":"Ex vivo culture of CTCs: an emerging resource to guide Cancer therapy","volume":"75","author":"Maheswaran","year":"2015","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.cellsig.2024.111270_bb0090","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911908","article-title":"Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity","volume":"12","author":"Koch","year":"2020","journal-title":"EMBO Mol. Med."},{"issue":"8","key":"10.1016\/j.cellsig.2024.111270_bb0095","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat. Rev. Genet."},{"issue":"5670","key":"10.1016\/j.cellsig.2024.111270_bb0100","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","author":"Samuels","year":"2004","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.cellsig.2024.111270_bb0105","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1023\/B:APPT.0000045801.15585.dd","article-title":"PI3K-Akt pathway: its functions and alterations in human cancer","volume":"9","author":"Osaki","year":"2004","journal-title":"Apoptosis"},{"issue":"5835","key":"10.1016\/j.cellsig.2024.111270_bb0110","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1126\/science.1146073","article-title":"PI3K charges ahead","volume":"317","author":"Lee","year":"2007","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.cellsig.2024.111270_bb0115","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1073\/pnas.0701005104","article-title":"Rare cancer-specific mutations in PIK3CA show gain of function","volume":"104","author":"Gymnopoulos","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"29","key":"10.1016\/j.cellsig.2024.111270_bb0120","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1038\/onc.2008.40","article-title":"Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells","volume":"27","author":"Horn","year":"2008","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.cellsig.2024.111270_bb0125","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/gt.2009.149","article-title":"Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis","volume":"17","author":"Weber","year":"2010","journal-title":"Gene Ther."},{"issue":"9","key":"10.1016\/j.cellsig.2024.111270_bb0130","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3390\/cells9092129","article-title":"High sensitivity of circulating tumor cells derived from a colorectal Cancer patient for dual inhibition with AKT and mTOR inhibitors","volume":"9","author":"Smit","year":"2020","journal-title":"Cells"},{"issue":"7403","key":"10.1016\/j.cellsig.2024.111270_bb0135","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2024.111270_bb0140","doi-asserted-by":"crossref","first-page":"11479","DOI":"10.1038\/ncomms11479","article-title":"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.cellsig.2024.111270_bb0145","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"issue":"269","key":"10.1016\/j.cellsig.2024.111270_bb0150","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.cellsig.2024.111270_bb0155","first-page":"21","article-title":"Oncogenic mutations of PIK3CA in human cancers","volume":"347","author":"Samuels","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111270_bb0160","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13058-020-01284-9","article-title":"Frequency and spectrum of PIK3CA somatic mutations in breast cancer","volume":"22","author":"Mart\u00ednez-S\u00e1ez","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"6","key":"10.1016\/j.cellsig.2024.111270_bb0165","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1158\/1078-0432.CCR-17-2141","article-title":"PIK3CA C2 domain deletions Hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence, and are exquisitely sensitive to PI3Kalpha inhibitors","volume":"24","author":"Croessmann","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.cellsig.2024.111270_bb0170","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87623","article-title":"PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution","volume":"1","author":"Mirzaa","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.cellsig.2024.111270_bb0175","doi-asserted-by":"crossref","unstructured":"Ladraa, S., et al., PIK3CA gain-of-function mutation in adipose tissue induces metabolic reprogramming with Warburg-like effect and severe endocrine disruption. Sci. Adv. 8(49): p. eade7823.","DOI":"10.1126\/sciadv.ade7823"},{"issue":"10","key":"10.1016\/j.cellsig.2024.111270_bb0180","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1002\/ajmg.a.37758","article-title":"Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation","volume":"170","author":"Gripp","year":"2016","journal-title":"Am. J. Med. Genet. A"},{"issue":"4","key":"10.1016\/j.cellsig.2024.111270_bb0185","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jmoldx.2017.04.001","article-title":"Overgrowth syndromes caused by somatic variants in the phosphatidylinositol 3-kinase\/AKT\/mammalian target of rapamycin pathway","volume":"19","author":"Akgumus","year":"2017","journal-title":"J. Mol. Diagn."},{"issue":"24","key":"10.1016\/j.cellsig.2024.111270_bb0190","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1158\/0008-5472.CAN-15-1654","article-title":"Identification of variant-specific functions of PIK3CA by rapid phenotyping of rare mutations","volume":"75","author":"Dogruluk","year":"2015","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111270_bb0195","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s41467-018-03867-9","article-title":"Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients","volume":"9","author":"Chen","year":"2018","journal-title":"Nat. Commun."},{"issue":"48","key":"10.1016\/j.cellsig.2024.111270_bb0200","doi-asserted-by":"crossref","first-page":"20258","DOI":"10.1073\/pnas.0902369106","article-title":"Regulation of class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85\/p110\u03b1 and are disrupted in oncogenic p85 mutants","volume":"106","author":"Wu","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"41","key":"10.1016\/j.cellsig.2024.111270_bb0205","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1038\/onc.2008.244","article-title":"Class I PI3K in oncogenic cellular transformation","volume":"27","author":"Zhao","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.cellsig.2024.111270_bb0210","article-title":"Breast cancer resistance to chemotherapy: when should we suspect it and how can we prevent it?","volume":"70","author":"Prihantono, and M. Faruk","year":"2021","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.cellsig.2024.111270_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101063","article-title":"Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer","volume":"73","author":"Ou","year":"2024","journal-title":"Drug Resist. Updat."},{"issue":"7","key":"10.1016\/j.cellsig.2024.111270_bb0220","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/1078-0432.CCR-20-3652","article-title":"FDA approval summary: Alpelisib plus Fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast Cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2024.111270_bb0225","unstructured":"Luboff, A.J. and D.L. DeRemer, Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer. Ann. Pharmacother. 0(0): p. 10600280241241531."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656824002389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656824002389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:30:06Z","timestamp":1762317006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656824002389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":45,"alternative-id":["S0898656824002389"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2024.111270","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2024.111270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111270"}}